Proactive Investor Publishes Article on Pacific Therapeutics
ACCESSWIRE - Fri Jul 25, 7:32AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / July 25, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company"
Pacific Therapeutics and Vodis Innovative Pharmaceuticals Agree to Share Technologies to Deliver Cannabinoid Based Therapies
ACCESSWIRE - Thu Jul 17, 7:32AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / July 16, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC: PCFTF) (Frankfurt: 1P3) (the "Company"
FDA to Host Meeting on Patient Focused Drug Development for IPF
ACCESSWIRE - Wed Jul 16, 7:33AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / July 16, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC: PCFTF) (Frankfurt: 1P3) (the "Company"
Expiry of Chinese Patent for Erectile Dysfunction Drug Opens Additional Market Opportunity
ACCESSWIRE - Fri Jul 11, 7:35AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / July 11, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC: PCFTF) (Frankfurt: 1P3) (the "Company"
Combination Treatment for Pulmonary Fibrosis Demonstrates Significant Disease Improvement in Pre-Clinical Trial
ACCESSWIRE - Wed Jul 09, 7:35AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / July 9, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC: PCFTF) (Frankfurt: 1P3) (the "Company"
European Patent Office Grants Patent for PTL-202, a Treatment for Idiopathic Pulmonary Fibrosis, a $1.1 Billion Opportunity
ACCESSWIRE - Mon Jul 07, 7:32AM CDT
VANCOUVER, BC / ACCESSWIRE / July 7, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC: PCFTF) (Frankfurt: 1P3) (the "Company"
Pacific Therapeutics Plans For Clinical Trial Timely In Light of Increasing Prevalence of Pulmonary Fibrosis
ACCESSWIRE - Thu Jul 03, 1:53AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / July 2, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC: PCFTF) (Frankfurt: 1P3) (the "Company"
Pacific Therapeutics Announces Directors Options
ACCESSWIRE - Fri Jun 27, 3:35PM CDT
VANCOUVER, BC / ACCESSWIRE / June 27, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC: PCFTF) (Frankfurt: 1P3) (the "Company"
Liver Cirrhosis - Pipeline Review, H1 2014
M2 - Tue Jun 10, 4:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tdw2pl/liver_cirrhosis) has announced the addition of the "Liver Cirrhosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Liver Cirrhosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Cirrhosis and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Companies Mentioned: - Nitto Denko Corporation - Galectin Therapeutics, Inc. - Digna Biotech, S.L. - Phenex Pharmaceuticals AG - Tobira Therapeutics, Inc. - GNI Group Ltd. - Alfa Wassermann S.p.A - Pharmicell Co., Ltd. - PharmaIN Corporation - Stempeutics Research Private Limited - Pacific Therapeutics Ltd. - ACROVIS biostructures GmbH For more information visit http://www.researchandmarkets.com/research/td..._cirrhosis
Pacific Therapeutics Announces First Quarter 2014 Financial Results
ACCESSWIRE - Fri May 30, 7:15PM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / May 30, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTCBB: PCFTF) (Frankfurt: 1P3) (the "Company"
Pacific Therapeutics Signs Agreement with Broker Dealer Tripoint Global Equities LLC.
ACCESSWIRE - Thu May 15, 7:35AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / May 15, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC: PCFTF) (Frankfurt: 1P3) (the "Company"